NDATOPICALCREAM
Approved
Jul 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
EFUDEX (fluorouracil) by Pfizer is nucleic acid synthesis inhibitors [moa]. Approved for colorectal cancer, pancreatic cancer, gastric cancer and 1 more indications. First approved in 1970.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EFUDEX (fluorouracil) is a nucleoside metabolic inhibitor administered as a topical cream that blocks nucleic acid synthesis in rapidly dividing cancer cells. It is indicated for 20+ solid tumors including colorectal, pancreatic, gastric, breast, and head/neck cancers. The drug has been a foundational chemotherapy agent since FDA approval in 1970.
$0.021BPart D
LOE ApproachingDeclining
Mature, declining brand with minimal headcount; team focus likely on legacy management and generic transition planning rather than growth initiatives.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications (4)
Worked on EFUDEX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.